Table 3.
TLRa combined with photothermal therapy.
| Sub Classses | TLRa | Immunoadjuvants | Nanoparticles | Administration Route | Phototherapy | Tumor Model | References |
|---|---|---|---|---|---|---|---|
| TLR4 | LPS | Quercetin (inhibitor of HSP70) | Quercetin-loaded liposomes | N/A | AG-IR820 | TT | [146] |
| TLR7 | R837 | anti-CTLA4 | PLGA nanoparticles | intratumoral | ICG | 4T1,CT26 | [147] |
| TLR7/8 | IMDQ | N/A | calcium crosslinked polyaspartic acid nanocomplex(denoted as NanopIR/mpIM) | intratumoral | IR780 | CT26 | [148] |
| TLR7/8 | IMDQ | N/A | (folic acid (FA)-Poly(N,N-dimethylacrylamide)(PDMA)& CuS@OXA& Mannose-Poly(acetone oxime acrylamide) (PAA) |
intratumoral | copper sulfide (CuS) | CT-26 | [149] |
| TLR7/8 | R848 | N/A | semiconducting polymer nanoparticle (SPN) | intravenous | SPII Photothermal | 4T1 | [106] |
| TLR7/8 | R848 | anti-PD-1 | dendritic large-pore mesoporous silica nanoparticles(DLMSNs) | intravenous | copper sulfide (CuS) | MDA-MB-231,4T1 | [108] |
| TLR7/8 | R848 | αPD-1 | thermosensitive liposomes (TSLs) | intravenous | FeSO4 | Neu deletion (NDL) | [150] |
| TLR7/8 | R848 | anti-PD-L1 | polyethylene glycol-modified (PDA)&PEG NPs |
intravenous | carbon dots (CDs) | 4T1 | [151] |
| TLR7/8 | R848 | N/A | PLGA nanoparticles | intratumoral | ICG | RM9 | [152] |
| TLR7/8, TLR9 | R848, CpG ODN | N/A | RIC NPs&PLEL hydrogel | intratumoral | ICG | 4T1 | [109] |